Wealth Enhancement & Preservation of GA LLC Sells 932 Shares of Becton Dickinson and Co (NYSE:BDX)

Wealth Enhancement & Preservation of GA LLC lessened its holdings in shares of Becton Dickinson and Co (NYSE:BDX) by 32.1% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,974 shares of the medical instruments supplier’s stock after selling 932 shares during the period. Wealth Enhancement & Preservation of GA LLC’s holdings in Becton Dickinson and were worth $425,000 as of its most recent SEC filing.

Several other hedge funds have also made changes to their positions in the company. Vanguard Group Inc. boosted its holdings in shares of Becton Dickinson and by 4.4% during the 2nd quarter. Vanguard Group Inc. now owns 25,098,916 shares of the medical instruments supplier’s stock valued at $6,005,418,000 after buying an additional 1,059,636 shares in the last quarter. BlackRock Inc. boosted its stake in Becton Dickinson and by 9.2% in the 2nd quarter. BlackRock Inc. now owns 20,760,348 shares of the medical instruments supplier’s stock worth $4,967,327,000 after purchasing an additional 1,755,896 shares in the last quarter. FMR LLC boosted its stake in Becton Dickinson and by 35.7% in the 2nd quarter. FMR LLC now owns 12,360,686 shares of the medical instruments supplier’s stock worth $2,957,540,000 after purchasing an additional 3,253,254 shares in the last quarter. State Street Corp boosted its stake in Becton Dickinson and by 0.3% in the 1st quarter. State Street Corp now owns 11,490,473 shares of the medical instruments supplier’s stock worth $2,640,166,000 after purchasing an additional 39,890 shares in the last quarter. Finally, Wellington Management Group LLP boosted its stake in Becton Dickinson and by 225.4% in the 1st quarter. Wellington Management Group LLP now owns 8,473,220 shares of the medical instruments supplier’s stock worth $1,946,892,000 after purchasing an additional 5,869,236 shares in the last quarter. Hedge funds and other institutional investors own 84.18% of the company’s stock.

A number of equities analysts recently issued reports on the stock. Barclays upgraded shares of Becton Dickinson and from an “equal weight” rating to an “overweight” rating and set a $300.00 price target on the stock in a research note on Thursday, July 9th. Goldman Sachs Group assumed coverage on shares of Becton Dickinson and in a research note on Sunday, May 31st. They issued a “buy” rating and a $278.00 price target on the stock. UBS Group upped their price target on shares of Becton Dickinson and from $265.00 to $280.00 and gave the stock a “neutral” rating in a research note on Monday, August 10th. William Blair restated an “outperform” rating on shares of Becton Dickinson and in a research note on Thursday, July 2nd. Finally, Zacks Investment Research cut shares of Becton Dickinson and from a “hold” rating to a “sell” rating and set a $245.00 target price on the stock. in a research note on Wednesday, May 27th. One analyst has rated the stock with a sell rating, seven have assigned a hold rating and eight have assigned a buy rating to the company. The stock currently has an average rating of “Hold” and a consensus target price of $279.47.

In related news, EVP Patrick Kaltenbach sold 1,272 shares of the stock in a transaction that occurred on Thursday, July 9th. The shares were sold at an average price of $260.00, for a total value of $330,720.00. Following the completion of the sale, the executive vice president now directly owns 10,340 shares of the company’s stock, valued at approximately $2,688,400. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 0.12% of the company’s stock.

Shares of NYSE BDX traded up $0.88 during midday trading on Wednesday, hitting $227.03. 2,480,400 shares of the company’s stock traded hands, compared to its average volume of 1,998,229. Becton Dickinson and Co has a 1 year low of $197.75 and a 1 year high of $286.72. The stock has a market capitalization of $68.38 billion, a price-to-earnings ratio of 82.14, a price-to-earnings-growth ratio of 3.00 and a beta of 0.85. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.97 and a current ratio of 1.45. The firm has a fifty day moving average of $254.55 and a 200 day moving average of $247.51.

Becton Dickinson and (NYSE:BDX) last released its quarterly earnings results on Thursday, August 6th. The medical instruments supplier reported $2.20 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $2.04 by $0.16. Becton Dickinson and had a net margin of 5.30% and a return on equity of 14.19%. The firm had revenue of $3.86 billion during the quarter, compared to analyst estimates of $3.96 billion. During the same quarter in the prior year, the firm earned $3.08 EPS. The business’s revenue for the quarter was down 11.4% compared to the same quarter last year. On average, equities analysts anticipate that Becton Dickinson and Co will post 9.9 earnings per share for the current year.

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, September 30th. Stockholders of record on Wednesday, September 9th will be given a dividend of $0.79 per share. This represents a $3.16 annualized dividend and a dividend yield of 1.39%. The ex-dividend date of this dividend is Tuesday, September 8th. Becton Dickinson and’s payout ratio is currently 27.05%.

Becton Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.

Read More: Diversification For Individual Investors

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton Dickinson and Co (NYSE:BDX).

Institutional Ownership by Quarter for Becton Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.